Stability and impact of diabetes distress over time: The potential value and uses of the type 1 diabetes distress assessment system (T1-DDAS).

IF 3.2 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Diabetic Medicine Pub Date : 2025-05-08 DOI:10.1111/dme.70066

Danielle M Hessler, William H Polonsky, Lisa Strycker, Diana Naranjo, Katherine Greenberg, Lawrence Fisher

{"title":"Stability and impact of diabetes distress over time: The potential value and uses of the type 1 diabetes distress assessment system (T1-DDAS).","authors":"Danielle M Hessler, William H Polonsky, Lisa Strycker, Diana Naranjo, Katherine Greenberg, Lawrence Fisher","doi":"10.1111/dme.70066","DOIUrl":null,"url":null,"abstract":"Aims: To document stability and change over time, define a minimal clinically important difference (MCID), and examine the predictive validity of the new Type 1 Diabetes Distress Assessment System (T1-DDAS).Methods: A total of 574 adults with type 1 diabetes recruited through national registries and previous studies completed the T1-DDAS Core and Source scales alongside a report of insulin taking and glycaemic measures at baseline and 6 months later.Results: The MCID for the T1-DAS is ±0.27. T1-DDAS scores were highly stable over 6 months: 88% of individuals with elevated Core Diabetes Distress (DD) in the study continued to report elevated DD at or above the 2.0 threshold 6 months later; 57% reported no improvement or a worsening in Core DD based on MCID. Elevated DD at baseline was linked to worsening in reported missed insulin bolus taking and HbA1c at 6 months.Conclusions: Findings add to our understanding of DD and the utility of the T1-DDAS by demonstrating the stability and predictive validity of the T1-DDAS Core and Source scales to assess DD.","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":" ","pages":"e70066"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dme.70066","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To document stability and change over time, define a minimal clinically important difference (MCID), and examine the predictive validity of the new Type 1 Diabetes Distress Assessment System (T1-DDAS).

Methods: A total of 574 adults with type 1 diabetes recruited through national registries and previous studies completed the T1-DDAS Core and Source scales alongside a report of insulin taking and glycaemic measures at baseline and 6 months later.

Results: The MCID for the T1-DAS is ±0.27. T1-DDAS scores were highly stable over 6 months: 88% of individuals with elevated Core Diabetes Distress (DD) in the study continued to report elevated DD at or above the 2.0 threshold 6 months later; 57% reported no improvement or a worsening in Core DD based on MCID. Elevated DD at baseline was linked to worsening in reported missed insulin bolus taking and HbA1c at 6 months.

Conclusions: Findings add to our understanding of DD and the utility of the T1-DDAS by demonstrating the stability and predictive validity of the T1-DDAS Core and Source scales to assess DD.

查看原文本刊更多论文

糖尿病窘迫随时间的稳定性和影响：1型糖尿病窘迫评估系统（T1-DDAS）的潜在价值和用途

目的：记录稳定性和随时间的变化，定义最小临床重要差异（MCID），并检查新的1型糖尿病痛苦评估系统（T1-DDAS）的预测有效性。方法：通过国家登记处和先前的研究招募了574名成人1型糖尿病患者，完成了T1-DDAS核心和来源量表，并报告了基线和6个月后的胰岛素服用和血糖测量。结果：T1-DAS的MCID为±0.27。T1-DDAS评分在6个月内高度稳定：研究中88%的核心糖尿病窘迫（DD）升高的个体在6个月后继续报告DD升高达到或高于2.0阈值；57%的患者报告基于MCID的核心DD没有改善或恶化。基线DD升高与6个月时报告的未按时注射胰岛素和HbA1c恶化有关。结论：研究结果通过证明T1-DDAS核心和源量表评估DD的稳定性和预测有效性，增加了我们对DD的理解和T1-DDAS的效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetic Medicine 医学-内分泌学与代谢

CiteScore

7.20

自引率

5.70%

发文量

229

审稿时长

3-6 weeks

期刊介绍： Diabetic Medicine, the official journal of Diabetes UK, is published monthly simultaneously, in print and online editions. The journal publishes a range of key information on all clinical aspects of diabetes mellitus, ranging from human genetic studies through clinical physiology and trials to diabetes epidemiology. We do not publish original animal or cell culture studies unless they are part of a study of clinical diabetes involving humans. Categories of publication include research articles, reviews, editorials, commentaries, and correspondence. All material is peer-reviewed. We aim to disseminate knowledge about diabetes research with the goal of improving the management of people with diabetes. The journal therefore seeks to provide a forum for the exchange of ideas between clinicians and researchers worldwide. Topics covered are of importance to all healthcare professionals working with people with diabetes, whether in primary care or specialist services. Surplus generated from the sale of Diabetic Medicine is used by Diabetes UK to know diabetes better and fight diabetes more effectively on behalf of all people affected by and at risk of diabetes as well as their families and carers.”